Anterix stock hits all-time high of 112.18 USD

Anterix stock hits all-time high of 112.18 USD

Anterix stock hits all-time high of 112.18 USD
New permanent community space will provide year-round access to soccer, mentorship, and life-skills programming for families in fire-affected neighborhoods ALTADENA, Calif., July 9, 2026 /PRNewswire/ — UNIQLO and Street Soccer USA today announced the opening of the UNIQLO Street Soccer Park & Learning Center in Altadena, a permanent community hub created to support youth and…
meshaphoto / Getty Images Commitment to Our Readers GOBankingRates’ editorial team is committed to bringing you unbiased reviews and information. We use data-driven methodologies to evaluate financial products and services – our reviews and ratings are not influenced by advertisers. You can read more about our editorial guidelines and our products and services review methodology….
What pharma is really doing: AI’s first killer app isn’t discovery, it’s the commercial machine !“#$%&‘()*+,–./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|} !“#$%&‘()*+,–./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}
Key insight: As written, new capital standards for U.S. banks fail to account for the additional risk posed by many home loan clients who obtain second mortgages. Fixing the problem will significantly reduce the rule’s benefit to banks. What’s at stake: The new capital standards create incentives to move second liens off bank balance sheets…
Donald Trump, President of the United States, speaks during a press conference at the NATO Summit at the Presidential Complex in Ankara, Turkiye, on July 8, 2026. (Photo by Klaudia Radecka/NurPhoto via Getty Images) Nurphoto | Nurphoto | Getty Images President Donald Trump threatened to “decimate and destroy” Iran if Tehran acts on threats to…
(RTTNews) – Today’s top biotech gainers include Zhengye Biotechnology, a veterinary vaccine manufacturer, which surged, easing Nasdaq delisting concerns; Advanced Biomed, which gained after withdrawing its planned U.S. securities offering and reducing potential dilution concerns; Neuronetics, following the appointment of a new CFO; and Armata Pharmaceuticals, which advanced its Phase 3 pathway for lead bacteriophage…